



UNIVERSITY *of*
RWANDA

**PREVALENCE OF OPPORTUNISTIC INFECTIONS AND
ASSOCIATED FACTORS AMONG HIV-INFECTED PERSONS
AGED ABOVE 15 YEARS ON ART IN RUHENGERI REFFERAL
HOSPITAL FROM 2007-2017**

ITANGA Inès

College of Medicine and Health Sciences (CMHS)

School of Public Health (SPH)

Department of Biostatistics and Epidemiology

Masters of Science in Field Epidemiology and Laboratory Management

Supervisor: Prof Joseph NTAGANIRA

Kigali, October 2019



UNIVERSITY *of*
RWANDA

**PREVALENCE OF OPPORTUNISTIC INFECTIONS AND
ASSOCIATED FACTORS AMONG HIV-INFECTED PERSONS
AGED ABOVE 15 YEARS ON ART IN RUHENGERI REFFERAL
HOSPITAL FROM 2007-2017**

A dissertation submitted in partial fulfillment of the requirements for the degree of
MASTERS OF SCIENCE IN FIELD EPIDEMIOLOGY AND LABORATORY
MANAGEMENT

In the College of Medicine and Health Sciences

ITANGA Inès

Registration number: 217296467

Supervisor: Prof Joseph NTAGANIRA

Kigali, October 2019

DECLARATION

I, **ITANGA Inès**, HEREBY DECLARE THAT THE THESIS HAS BEEN WRITTEN BY ME WITHOUT ANY EXTERNAL UNAUTHORIZED HELP, THAT IT HAS BEEN NEITHER PRESENTED TO ANY INSTITUTION FOR EVALUATION NOR PREVIOUSLY PUBLISHED IN ITS ENTIRETY OR IN PARTS. ANY PARTS, WORDS OR IDEAS OF THE THESIS, HOWEVER LIMITED, WHICH ARE QUOTED FROM OR BASED ON OTHER SOURCES, HAVE BEEN ACKNOWLEDGED AS SUCH WITHOUT EXCEPTION.

ABSTRACT

Background

Human immunodeficiency virus (HIV) pandemic is the greatest health crises ever faced by humanity. It causes progressive weakening of the immune system, leading to opportunistic infections (OIs) or malignancies during the natural course of the disease. This study aimed at assessing the prevalence and factors associated with occurrence of OIs among adults patients on ART in Ruhengeri referral hospital.

Methodology

A descriptive cross-sectional and analytical study was performed by reviewing data of HIV positive adult patients (≥ 15 years) on ART enrolled at Ruhengeri referral hospital from 1st January 2007 to 31st December 2017. Opportunistic infections were based on clinical diagnosis. The prevalence of OIs was determined as the proportion of HIV/AIDS patients on ART who developed one or more OIs. Crude and adjusted odds ratios (CORs and AORs), respectively with 95% confidence intervals (CIs) was used to describe the strength of association between OIs and possible risk factors.

Results

The mean age of participants was 43 (SD \pm 11.5) and female were majority (64.1%). Pre- ART has been provided to almost all participants (97.6%) and 75.7% of participants had spent more than five years on ART. Among participants, 40.2% were at WHO clinical stage I, 61.2% had CD4 count between 200 and 499, and 92.2% were at 1st line regimen. Out of 423 patients, 39 had diagnosed OIs (9.2%). Frequent OIs were tuberculosis (20%), oral candidiasis (15.6), pneumonia (15.6%) and STI (15.6%). The independent risk factors for developing OIs were being jobless (Adjusted odds ratio [AOR] = 5.03, 95% CI= 2.13, 32.99), spending more than five years on ART (AOR= 4.34, 95% CI= 1.12-16.78) and starting ART at WHO clinical stage III (AOR= 4.88, 95% CI= 1.65-16.78).

Conclusion

Opportunistic infections remain a challenge among patients receiving antiretroviral therapy (ART) in Ruhengeri referral hospital. There is need to strengthen the management of opportunistic infections despite the use of ART.

Key words: HIV, Opportunistic infections, Antiretroviral therapy, Ruhengeri RH

DEDICATION

“This work is dedicated to my special friend who supported me unconditionally in many ways, to my parents, my daughters GAJU Hope and KAMIKAZI Linda, to my sister SAFI Emma and brother KABANDA Clovis. Without their caring support, it would not have been possible to complete this work. May God bless and keep you always”.

ACKNOWLEDGEMENT

This research could not have been done without the contribution of different people who deserve to be thanked.

Special thanks to the distinguished supervisor Professor Joseph NTAGANIRA for his guidance and encouragement throughout the course of preparing for and conducting the study.

I am thankful too for the support and advices from the other faculty members of the School of Public health especially FELTP staff who have generously given their time and expertise to teach us and enable us to do such a work. I recognize their contribution and their good natured support.

I should acknowledge as well staff from Ruhengeri Referral Hospital in ARV service for their support and collaboration during data collection. Especially, I need to express my gratitude and deep appreciation to Dr Jared OMOLO and Justine UMUTESI for the helpful comments provided on the draft of this work up to the end of this study.

Finally, to each and everyone who have contributed to my studies in one way to another, I express my gratitude.

May God bless you all.

LIST OF SYMBOLS AND ACRONYMS

AIDS:	Acquired Immune Deficiency Syndrome
ART:	Antiretroviral therapy
AOR:	Adjusted Odds Ratio
CD4	Cluster of Differentiation 4
CI:	Confidence Interval
COR:	Crude Odds Ratio
HAART	Highly Active Antiretroviral Therapy
HIV:	Human Immunodeficiency Virus
MOH:	Ministry of Health – Rwanda
OI:	Opportunistic Infection
PLWHIV:	People living with HIV
SPH:	School of Public Health
UNAIDS	United Nations Programme on HIV and AIDS
UR:	University of Rwanda
WHO:	World Health Organization

TABLE OF CONTENTS

DECLARATION	ii
DEDICATION	iv
ACKNOWLEDGEMENT	v
LIST OF SYMBOLS AND ACRONYMS	vi
I. INTRODUCTION	1
1. Background	1
2. Problem statement	2
3. Objectives of the study	3
3.1. Main objective	3
3.2. Specific objectives	3
4. Research questions	3
5. Justification of the study	3
6. Organization of the thesis	3
II. LITERATURE REVIEW	5
2.1. HIV and opportunistic infections	5
2.2. Prevalence of opportunistic infections among PLWHIV	6
2.3. Factors associated with opportunistic infections in HIV	7
2.4. ART and OIs	8
2.5. Conceptual framework	9
III. METHODOLOGY	10
1. Study setting	10
2. Study design	10
3. Study population	11
4. Sampling and sample size	11
5. Inclusion and exclusion criteria	11
6. Data collection and definition of variables	12
7. Data entry and analysis	12
8. Ethical considerations	14
IV. RESULTS	15
4.1. Social demographic characteristics of study participants	15
4.2. Clinical characteristics of study participants	16
4.3. Prevalence of Opportunistic infections	17
4.4. Risk factors	17
V. DISCUSSIONS OF THE RESULTS	22
Study limitations	24
VI. CONCLUSION AND RECOMMENDATIONS	25
References	26

I. INTRODUCTION

1. Background

Opportunistic infections (OIs) are defined as more frequent or more serious infections due to immune suppression in HIV-infected individuals. They are the main clinical manifestations of HIV patients(1).

The occurrence of opportunistic infections may indirectly affect the natural course of HIV infection as HIV viral load increases in patients with acute opportunistic infections. . Survival of HIV-infected people has improved through an increasingly great range of antiretroviral therapy, but neurological symptoms due to comorbid situations are still important for the public health of HIV infected people. (2).

Severely immune compromised HIV patients may develop various opportunistic infections that have a significant impact on their well-being, quality of life, cost of health care and their survival. (3)

The risk of OI in HIV patients depends on exposure to potential pathogens, virulence of these agents, degree of host immunity, and use of antimicrobial prophylaxis(4).

The majority of OIs are associated with an increased risk of death in HIV patients. Patients with morbidity due to opportunistic diseases may be interrupted by antiretroviral therapy, resulting in more rapid progression of HIV disease. In addition, studies have shown that opportunistic infections lead to a positive regulation of HIV replication and a higher viral load(5).

Introduction and generalized access to antiretrovirals (ARVs) have revolutionized HIV / AIDS management and treatment leading to a dramatic improvement in the clinical course and survival in infected patients(6).

The impact of the introduction of highly active antiretroviral therapy (ART) on the incidence and mortality of human immunodeficiency virus (HIV)–associated opportunistic infections (OIs) has been well documented in high-income countries (HICs)(7)(8)

2. Problem statement

Globally, almost 23.3 million people were receiving antiretroviral treatment by end 2018. These 23.3 million of the 37.9 million people living with HIV globally are more than three times as many as in 2010. Access to ART has increased rapidly since 2005 from just 2.0 million to 23.3 million by the end of 2018. The estimated ART global coverage increased from 7% in 2005 to 62% in 2018. Treatment scale-up has seen deaths from AIDS-related illness decline from a peak of 1.7 million [1.3–2.4 million] in 2004 to 770 000 [570 000–1 100 000] in 2018.(9)

The greatest increase occurred in WHO African Region, where ART was uncommon up to 2005 (739 000 people on ART) and increased to 16.3 million in 2018. Regions that have made less progress are those in which the epidemic is predominantly concentrated in populations with lower access and utilization of services, such as sex workers, injecting drug users, and men who have sex with men. https://www.who.int/gho/hiv/epidemic_response/ART/en/

Rwandan government in collaboration with partners made efforts to avail ART in the country. These efforts resulted in drastically improvement of access to combination antiretroviral therapy (cART) from only 870 adults receiving cART in 2002 to 114,995 in 2013, which is more than 90% of the eligible HIV-infected population(10). Rwanda has also made impressive progress against the 90-90-90 targets, with 88% (198,000) of the 225,000 people living with HIV in the country diagnosed with HIV, 94% (187,000) of those diagnosed now on ART, and 91% of those on ART (170,000) achieving viral suppression.(11)

Studies on the prevalence of OIs among PLWHIV on ART have been conducted in a number of settings(8,12–16) Some others have analyzed the associated factors(17–19).

In Rwanda, only one report has been done by SPH in 2013 on Prevalence of HIV/AIDS related Opportunistic Infections among HIV Positive Patients(20), but never published in peer review journals.

3. Objectives of the study

3.1. Main objective

To determine the prevalence of opportunistic infections and associated factors among HIV-Infected Adults on ART followed at Ruhengeri referral hospital from 2007 to 2017.

3.2. Specific objectives

1. To determine the prevalence of different OIs among adult patients on ART in Ruhengeri referral hospital(RRH)
2. To identify factors associated with occurrence of OIs among adult patients on ART in Ruhengeri referral hospital

4. Research questions

1. What is the prevalence of HIV related OIs among adults on ART in Ruhengeri referral hospital?
2. What are factors associated with OIs occurrence among adult PLWHIV on ART in Ruhengeri referral hospital?

5. Justification of the study

Results from this study will be used by RBC to understand the burden of opportunistic infections among HIV positive patients on ART. Through this study, risk factors associated with OIs occurrence among adult patients on ART will be known and preventive measures may be taken where possible. Results will also be used to strengthen management of adult PLWHIV on ART. This study reveals as well weakness of the current patients' management system from which plans for improvement may be developed.

6. Organization of the thesis

This thesis is divided into six chapters:

- Introduction: this chapter gives the background, problem statement, objectives, research questions, justification of the study and the organization of the study.
- Literature review: this part is all about what is known about HIV and OIs
- Methodology: will give details about how results were found.
- Results: this chapter concerns findings from data used for the study

- Discussions of the results: Compares the results of this study with other research done worldwide in the same context. It also presents limitations encountered
- Conclusion and recommendations: from findings of the study, recommendations are developed
- References

II. LITERATURE REVIEW

2.1. HIV and opportunistic infections

The pandemic of human immunodeficiency virus (HIV) is one of the biggest health crises ever faced by mankind. Overall, 36.9 million people were living with HIV at the end of 2017. Sub-Saharan Africa remains the most severely affected, with 53% of people living with HIV globally(21)

AIDS (acquired immunodeficiency syndrome) appeared epidemically in the 1980's. It is an advanced clinical manifestation of infection with human immunodeficiency virus (HIV), characterized by low lymphocyte count CD4 + below 200 / mm³(22).

Human immunodeficiency virus (HIV) causes progressive weakening of the immune system, leading to opportunistic infections (OIs) or malignancies during the natural course of the disease (23–26). Opportunistic infections can be due to viral pathogens, bacteria, fungi, or protozoa (27–30)

Characteristically, an HIV infection can progress for eight to ten years before the clinical syndrome (AIDS) occurs. The long latent period of the virus has contributed to many of the problems relating to diagnosis and control. On the other hand, not all cases exhibit the long latent period, and abrupt progression to AIDS occurs. Many factors, including genetics, determine the speed at which the disease will progress in a given individual(22)

Initiation of ART has the role of reducing the amount of virus in human body (viral load) to undetectable levels with current blood tests, to improve the immune reconstitution thus reducing the incidence of OIs. It also reduces the transmission of HIV, minimizes the risk of resistance as well as long term toxicity and minimizes the cost of care(31).

In recent years, scientific research has clearly demonstrated the clinical benefits of earlier initiation of antiretroviral treatment (ART), as well as showing that ART can markedly reduce HIV transmission to sexual partners. These results are reflected in the 2013 global guidance from WHO that recommends initiation of ART at a CD4 count of 500 cells/mm³ or less, and in certain populations regardless of CD4 count, including people with tuberculosis (TB) and active Hepatitis B (HBV), people with HIV-negative partners and all pregnant women living with HIV.

The new recommendations increase the number of people eligible for ART globally from around 17 million under 2010 guidelines to more than 28 million(14)

2.2. Prevalence of opportunistic infections among PLWHIV

Before widespread use of potent combination of the antiretroviral therapy (HAART), opportunistic diseases, which were defined as infections that are more frequent or more severe because of immunosuppression in HIV-infected people, were the leading cause of morbidity and mortality in the population during the natural course of the disease(13)

Studies show that the major comorbidities associated with AIDS are candidiasis, followed by tuberculosis, pneumocystosis, toxoplasmosis, herpes, Kaposi's sarcoma, cryptococcosis, and infections by protozoa(32).

While opportunistic infections count around 99% of morbidity in HIV infected person, opportunistic cancers were only counting 1% in Uganda(19)(33). In 2013, Uganda counting 21168 opportunistic infections and the main causes were geohelminths (30.7%), diarrheal infections (25.5%), oral candida (19.4%), Tuberculosis (18.3%), bacterial pneumonia (14.8%), genital ulcers (10%) and 10% for others, this was generally more prevalent in women than in man(19). With age, HIV treatment with antiretroviral is covered for almost all patients and patterns of opportunistic infection changed compared to the data of 2013. The study carried out in Uganda 3 years after, the prevalence of opportunistic infection changed and some infections were covered; the most common was oropharyngeal candidiasis (43.6%), the following was tuberculosis (21.6%), the third was herpes zoster (19.9%) and the next one was cryptococcal meningitis (4.6%)(34).

The study conducted in Ethiopia showed that among the HIV infected person, the overall prevalence of opportunistic infections was 42.8%. Some patients were having more than one opportunistic infection and the prevalence was as follow: (61%) of patients were having only 1 opportunistic infection, 34.8% of patients were having two opportunistic infections, 3.5% of patients were having three opportunistic infections and 0.7% were having four and plus opportunistic infections. Referred to the type of opportunistic infection, Esophageal candidiasis was the most prevalent with 4.5%, followed by bacterial pneumonia with 3.1%, Pneumocystic

pneumonia was having 2.8%, while *Cryptococcus meningitis* and septicemia were having 0.5% for each(35).

Tuberculosis is among the commonest opportunistic infection among HIV infected person, this was found in the study conducted in Tanzania where the prevalence of tuberculosis among people living with HIV was 11% and some factors were associated with this opportunistic infection such as grater clinical stage (3 and 4), lower CD4 while on treatment, male gender, etc (36)

A study conducted in Kenya showed that the overall prevalence of opportunistic infection was 14.1 %. The highly notified opportunistic among HIV infected person in Kenya were including related bacterial infections such as pulmonary tuberculosis, pneumonia bacterial with a prevalence of 3.6% and 6.4% respectively; related fungal infections such as oral candidiasis, esophageal candidiasis, pneumocystic jiroveci pneumonia and fungal skin Infection on the prevalence of 0.6%, 0.3%, 0.3% and 0.6% respectively; related viral infection such as herpes infection (HSV and HZV) and hepatitis C virus infection with a prevalence of 0.6% and 0.3% respectively; related parasitic infection such as worms with a prevalence of 0.3%; related malignancy such as Kaposi sarcoma and invasive cervix carcinoma with a prevalence of 0.6% and 0.3% respectively; other opportunistic infection were including wasting syndrome and diarrhea with a prevalence of 0.3% and 1.0% respectively(35).

2.3. Factors associated with opportunistic infections in HIV

Despite the HAART era, the OIs continue to cause considerable morbidity and mortality in HIV-infected patients. This is due to three primary reasons: asymptomatic patients seek medical assistance only when an OI becomes an indicator of AIDS; other patients do not make use of HAART for psychosocial and economic factors; and there are still those who do not have a good response to antiretroviral agents due to poor adherence, drug toxicity, drug interactions or unexplained biological factors.

The highest incidence of opportunistic infections was reported in the group of patients with CD4 lymphocyte levels below 200 cells/ mm³(17). The relationship between HIV and OIs is based on immunosuppression(15). It is also known that the risk of developing OI is high as the WHO

clinical stages increase; meaning the more there is a delay in starting ART, the more the patient health is at risk.(28)(37)

Apart from the clinical factors known to be associated with opportunistic infection there are social demographic factors that are known to associated with OIs as well. Those are age which is explained by the fact that older patients immune get decreased while the viral load gets increased, this predisposing them for opportunistic infections.(38)

Employment has been found to be associated with opportunistic infections, where Commercial sex workers are more at risk of having Opportunistic infections.(39)

Gender has its role in development of OIs as it has been found that males present late for ART when compared with their female counterparts. This may partly explain their poorer outcomes in comparison to females.(40,41)

Behavior has its role in predisposing people to develop opportunistic infections. Studies have shown a significant association between opportunistic infection and smoking and/or alcohol use.(42)

2.4. ART and OIs

The world has committed to ending the AIDS epidemic by 2030(26). The UNAIDS data, covering 160 countries, demonstrate both the enormous gains already made and what can be achieved in the coming years through a Fast-Track approach. In just two years (2013-2015), the number of people living with HIV on antiretroviral therapy has increased by about a third, reaching 17.0 million people—2 million more than the 15 million by 2015 target set by the United Nations General Assembly in 2011(26)


Antiretroviral therapy in the developed world has resulted in substantial reductions in HIV-associated morbidity and mortality, changing an HIV diagnosis from a likely death sentence into a manageable chronic infection. Several million years of life have been saved by effective anti-HIV treatment, although these successes should not obscure the magnitude of the ongoing worldwide HIV epidemic(16).

In LMICs the deployment of antiretroviral therapy (ART) has led to over 15 million patients on ART and a decrease of HIV- related deaths by 40% since 2004(43). In sub-Saharan Africa, the number of AIDS-related deaths fell by 39% between 2005 and 2013(44). The region still

accounted for 74% of all the people dying from AIDS-related causes in 2013(12). In the Caribbean, it declined by 54% and in Latin America by 31%(12,44,45).

The results from using antiretroviral therapy (ART) to control the incidence and mortality of human immunodeficiency virus (HIV) – associated opportunistic infections (OIs) have been well documented in high-income countries (HICs). Though there have been great achievement assuring survival of people living with HIV, a progressive shift in the pattern of co-morbidities, with an increasing contribution of chronic liver disease due to hepatitis C and B, tuberculosis, cardiovascular disease, and non-AIDs malignancies is observed(37,46–49).

2.5. Conceptual framework



METHODOLOGY

1. Study setting

Ruhengeri RH is a health facility located in Musanze District, Northern Province of Rwanda. The District is bordered by the Republic of Uganda and Democratic Republic of Congo (DRC) to the North through Virunga National Park, Gakenke District in the South, Burera District to the East, Nyabihu in West and Ruhondo Lake in the South West. The district has 15 sectors, 68 cells and 432 villages.

Ruhengeri RH was built in 1939 during the colonial period. It started its activities as a public clinic from 1939 to 1964 and in the 1980's it was recognized as the national referral hospital. Since 1999, Ruhengeri hospital became district hospital but continue to receive transfers from others neighboring district hospital.

Ruhengeri RH serves more than 374,000 populations coming from 15 health Centers. It carries out regularly clinical and technical supervision to the health facilities in its catchment area. The hospital has ARV as one of clinical services working under internal medicine department. When data were being collected, this service had around 1500 patients on ART coming not only from Musanze district but also from neighboring districts. The service is staffed by 4 nurses, 1 social work, 1 doctor mentor and 1 nurse mentor working 7/7 days. Nurses and social workers are permanently in the service but the doctor has the task of mentoring health centers as well. This makes a non permanent availability of doctor in ARV service. When an HIV patient has a health problem out of his/her appointment, he/she is received by outpatient department of internal medicine and treated as all other patients, using a patient' file different from the one kept in ARV service. The history is recorded in his/her ARV file when he remembers to tell it to a nurse/doctor on his/her appointment day.

2. Study design

We performed a descriptive cross sectional study to analyze the prevalence and factors associated with opportunistic infections by reviewing data of HIV positive adult patients (≥ 15 years) on ART enrolled at Ruhengeri referral hospital from 1st January 2007 to 31st December 2017.

3. Study population

The study considered HIV positive adults people (≥ 15 years old) on ART, enrolled in Ruhengeri RH and who started ART since 2007.

4. Sampling and sample size

Given that the prevalence of OIs among patients on ARV is unknown in Rwanda, the sample size was based on the assumption that the expected prevalence of OIs among patients on ART is the same in the region, thus referring to the study conducted on Magnitude of opportunistic infections and associated factors in HIV-infected adults on antiretroviral therapy in eastern Ethiopia where the overall prevalence of OIs was 48%, was used as reference with 95% confidence interval and a margin of error of 5%. A 10% was added to fill in possible missing data during collection or entry. We enrolled 423 participants to the study by applying the following formula:

$$n = \frac{(z_{1-\alpha/2})^2 p(1-p)}{d^2}$$

With n = Sample size
($z_{1-\alpha/2}$) = Confidence level
p = Prevalence
d = margin of error

$$n = \frac{(1.96)^2 0.48(0.52)}{0.05^2}$$
$$n = 383.54 \sim 384$$
$$n = 384 + 10\% \text{ of } 384 = \mathbf{423}$$

A systematic random sampling was applied to obtain the required sample. We had a total of 862 files of adult patients on ART for the period 2007 – 2017. To get the required sample we calculated k (Interval) by dividing 862 by 423. We obtained 2.03. Therefore we chose a starting point randomly and took every 2nd file until we got the sample size needed.

5. Inclusion and exclusion criteria

- To be included in the study, participants had to be HIV positive patients who started ART between 1st January 2007 and 31st December 2017, aged 15 years or more.
- Exclusion criteria was patients who are not on ART or who are aged less than 15 years or who started ART before 1st January 2007 or after 31st December 2017

6. Data collection and definition of variables

Medical records were retrospectively reviewed to extract data on adult cases that started treatment during the period of 2007 to 2017. Opportunistic infections were based on clinical diagnosis. Data extraction tool was designed in Excel, and completed by nurses in ART services.

The following variables were recorded:

Outcome variables: Has developed one or more opportunistic infection.

Independent variables:

- **Socio-demographic variables:** Gender, age, Occupation, marital status, education and residence
- **Clinical variables**
 1. Date of ART starting
 2. WHO clinical stage at ART initiation
 3. CD4 count at ART Initiation
 4. ART regimen line
 5. Diseases diagnosed after ART initiation
 6. Dates of consultation after ART initiation
 7. Adherence to ART
 8. Side effects

7. Data entry and analysis

Data collected was recorded using Excel then analyzed using STATA. Descriptive statistics was computed to determine frequencies and summary statistics (mean, standard deviation, and percentage) to describe the study population in relation to socio-demographic and other relevant variables. The prevalence of OIs was determined as the proportion of HIV/AIDS patients on ART who had one or more of the following diseases:

a. Viral pathogens

1. Epstein barr virus (EBV)
2. Hepatitis B Virus (HBV)
3. Hepatitis C Virus (HCV)
4. Hesper simplex virus (HSV)
5. Human herpes virus 8 (HHV-8)
6. Cytomegalovirus (CMV)
7. Human papilloma virus (HPV)

8. John Cunningham (JC) virus

b. Bacterial diseases

- 9. Mycobacterium tuberculosis (TB)
- 10. Mycobacterium avium complex (MAC)
- 11. Syphilis
- 12. Bacterial respiratory disease
- 13. Bacterial enteric disease**
- 14. Bartonellosis**

c. Fungal diseases

- 15. Pneumocystis jiroveci pneumonia
- 16. Mucocutaneous candidiasis
- 17. Cryptococcosis
- 18. Histoplasmosis
- 19. Coccidiomycosis
- 20. Aspergillosis
- 21. Penicilliosis

d. Protozoan diseases

- 22. Toxoplasmosis
- 23. Cryptosporidiosis
- 24. Microsporidiosis
- 25. Malaria
- 26. Leishmaniasis
- 27. Chagas disease
- 28. Onchocerciasis

ART adherence is assessed using tablet counting method where medication records for patients is matched by the nurse in-charge against the not-yet-used medicines brought to ARV service by the patients as a routine for refill of prescriptions and the number of doses that ought to have been taken that is missed is recorded. Patients are said to have ART adherence below 95% if they missed more than 5% of their doses on his RDV.

Univariate and multivariate analysis logistic regression models were used to describe the association between OIs and possible risk factors. Crude and adjusted odds ratios (CORs and AORs), respectively with 95% confidence intervals (CIs) was used to describe the strength of the

association between the selected study variables. The criterion for significance was set at $p \leq 0.05$ based on a two-sided test.

8. Ethical considerations

The study protocol was approved by the Ethical Review Committee of the College of Medicine and Health Sciences at University of Rwanda. All required information was collected by the staff working in the ART service, and the analysis was conducted after removing the registration number in the dataset to ensure the confidentiality of clinical records.

IV. RESULTS

4.1. Social demographic characteristics of study participants

A total of 423 records from HIV/AIDS patients on ART were reviewed. The mean age of participants was 43 (SD±11.5) years and ranging from 15-83 years. Most of the patients were in age group of 45-54 years (33.8%), were female (64.1%), living in urban area (85.6%), married (42.8%), farmers (54.6%) and had primary educational level (57.2%).(Table 1)

Table 1: Socio demographic characteristics of Adults on ART at Ruhengeri Referral Hospital from 2007-2017

Variables	Frequency (n)	Percent
Gender (n=423)		
Female	271	64.1
Male	152	35.9
Age (n=423)		
15-24	35	8.3
25-34	48	11.4
35-44	137	32.4
45-54	143	33.8
>55	60	14.2
Residence (n=423)		
Rural	61	14.4
Urban	362	85.6
Educational level (n=423)		
None	86	20.3
Primary	242	57.2
Secondary	86	20.3
University	9	2.1
Marital status (n=423)		
Divorced	39	9.2
Married	181	42.8
Single	104	24.6
Widower	99	23.4
Occupation (n=423)		
Farmer	231	54.6
Jobless	20	4.7
Paid employee	78	18.4
Self employed	69	16.3
Student	25	5.9

4.2. Clinical characteristics of study participants

Table 2 shows that Pre- ART has been provided to almost all participants (97.6%) and in December 2017, 75.7% of participants had spent more than five years on ART. At ART initiation most of participants were at WHO clinical stage I (40.2%), CD4 count were between 200-499 for the majority of participants (61.2%) and 92.2% were at 1st line regimen.

Table 2: Clinical characteristics of Adults on ART at Ruhengeri Referral Hospital from 2007-2017

Variables	Frequency (n)	Percent
Pre ART Provided (n=423)		
No	10	2.4
Yes	413	97.6
ART duration in Years (n=423)		
Below 5 years	103	24.4
Above 5 Years	320	75.7
WHO clinical stage (n=423)		
I	170	40.2
II	131	31.0
III	109	25.8
IV	13	3.1
CD4 count at ART Initiation (n=423)		
<200	121	28.6
200-499	259	61.2
>500	43	10.2
Regimen line (n=423)		
1 st	390	92.2
2 nd	32	7.57
3 rd	1	0.24

4.3. Prevalence of Opportunistic infections

Out of 423 patients, 39 had diagnosed OIs, representing an overall prevalence of 9.2%. There were a total of 16 OIs diagnosed in 39 patients. Among patients who developed OIs 10.3% (4/39) had at least two infections. The most frequent OIs were tuberculosis (20%) followed by oral candidiasis, pneumonia and STI with 15.6% each. (Table 3)

Table 3: Frequency of different types of OIs among HIV adults on ART at Ruhengeri referral hospital (2007–2017)

Diagnosed OIs	Freq.	Percent
Cutaneous mycoeces	1	2.2
Hepatitis B	2	4.4
Infectious dermatitis	1	2.2
Kaposi's sarcoma	1	2.2
Non bloody diarrhea	2	4.4
Onycomycoeces	2	4.4
Oral candidiasis	7	15.6
Oro-pharyngial candidiasis	1	2.2
Parotiditis	1	2.2
Pneumonia	7	15.6
Rheumatoid arthritis	1	2.2
STI	7	15.6
Skin lesion	1	2.2
Suppurative adenitis	1	2.2
Tuberculosis	9	20.0
Vaginal candidosis	1	2.2
Co-infection		
Cutaneous mycoses and Kaposi's sarcoma	1	2.2
Pneumonia and STI	1	2.2
Pneumonia and Skin lesion	1	2.2
STI, Pneumonia, Infectious dermatitis and parotiditis	1	2.2

4.4. Risk factors

Table 4 shows that socio-demographic variables which are significantly associated with the presence of opportunistic infections are Age where being aged between 35-44 years protects from developing OIs (OR= 0.28, 95% CI= 0.10, 0.82, p=0.02) compared to those aged below 25, and occupation where jobless are five times more likely to develop OIs compared to farmers

(OR= 5.01, 95% CI= 1.74, 14.79, p= 0.003). The risk of developing OIs among HIV patients on ART at Ruhengeri referral hospital does not vary with gender, marital status, educational level and residence. (Table 4)

Table 4: Univariate analysis of social demographic factors associated with opportunistic infections (OIs) among HIV patients on ART at Ruhengeri referral hospital

	Do not have OI Frequency (%)	Have OI Frequency (%)	COR (95%CI)	P-value
Gender (n=423)				
Female	249 (91.9)	22 (8.1)	1	0.30
Male	135 (88.8)	17 (11.9)	1.43 (0.73,2.78)	
Marital status (n=423)				
Divorced	37 (94.9)	2 (5.1)	1	0.82
Married	170 (93.2)	11 (6.1)	1.20 (0.25,5.63)	
Single	86 (82.3)	18 (17.3)	3.87 (0.85,17.54)	
Widower	91 (91.2)	8 (8.1)	1.63 (0.33,8.02)	
Age (n=423)				
15-24 yrs	28 (80)	7 (20)	1	0.52
25-34 yrs	41 (85.4)	7 (14.6)	0.68 (0.22,2.16)	
35-44 yrs	128 (93.4)	9 (6.6)	0.28 (0.10,0.82)	
45-54yrs	131 (91.6)	12 (8.4)	0.37 (0.13,1.01)	
55-64 yrs	50 (94.3)	3 (5.7)	0.24 (0.06,1.00)	
Over 65yrs	6 (85.7)	1 (14.3)	0.67 (0.07,6.47)	
Educational level (n=423)				
None	80 (93)	6 (7)	1	0.71
Primary	222 (91.7)	20 (8.3)	1.20 (0.46,3.10)	
Secondary	74 (86.1)	12 (13.9)	2.16 (0.77,6.05)	
University	8 (88.9)	1 (11.1)	1.67 (0.18,15.63)	
Residence (n=423)				
Rural	56 (91.8)	5 (8.2)	1	0.77
Urban	328 (90.6)	34 (9.4)	1.16 (0.43,3.09)	
Occupation (n=423)				
Farmer	213 (92.2)	18 (7.8)	1	0.003
Jobless	14 (70)	6 (30)	5.07 (1.74,14.79)	
Paid employee	76 (97.4)	2 (2.6)	0.31 (0.07,1.37)	
Self employed	61 (88.4)	8 (11.6)	1.55 (0.64,3.74)	
Student	20 (80)	5 (20)	2.96 (0.99,8.81)	

Among clinical variables associated with the presence of OIs, Adherence to ART above 95% is negatively associated with development of OIs (OR= 0.32, 95% CI= 0.14, 0.74, p= 0.007), those

who have spent more than five years on ART are four times at risk of having OIs compared to those who spent less than 5 years (OR= 4.2, 95% CI = 1.27, 14.02, p= 0.02) and those who started ART at WHO clinical stage II & III are 3 and 5 times respectively at risk of having OIs compared to those who started ART at WHO clinical stage I [WHO clinical stage II (OR=3.01, 95% CI= 1.11, 8.15, p= 0.03) and WHO clinical stage III (OR=5.4, 95% CI= 2.07,14.1, p= 0.001)]. CD4 has no effect on the occurrence of OIs and ART regimen as well. Receiving pre-ART or not, does not have any impact on development of OIs among HIV patients on ART at Ruhengeri referral hospital. (Table 5)

Table 5: Univariate analysis of clinical factors associated with opportunistic infections (OIs) among HIV patients on ART at Ruhengeri referral hospital

	Do not have OI Frequency (%)	Have OI Frequency (%)	COR (95%CI)	P-value
Adherence to ART (n=422)				
<95%	34 (79.1)	9 (20.1)	1	
>95%	349 (92.1)	30 (7.9)	0.32 (0.14,0.74)	0.007
ART period in years (n=423)				
< 5	100 (97.1)	3 (2.9)	1	
> 5	284 (88.7)	36 (11.3)	4.2 (1.27,14.02)	0.02
WHO clinical at ART initiation (n=423)				
I	164 (96.8)	6 (3.5)	1	
II	118 (90.1)	13 (9.9)	3.01 (1.11,8.15)	0.03
III	91 (83.5)	18 (16.5)	5.4 (2.07,14.1)	0.001
IV	11 (84.6)	2 (15.4)	5.0 (0.89,27.55)	0.07
CD4 count at ART initiation (n=423)				
>500	38 (88.4)	5(11.6)	1	
200-499	239 (92.3)	20 (7.7)	0.63 (0.22,1.79)	0.39
<200	107 (88.4)	14 (11.6)	0.99 (0.33,2.94)	0.99
ART Regimen line (n=423)				
1 st	353 (90.5)	37 (9.5)	1	
2 nd	30 (93.7)	2 (6.3)	0.64 (0.14,2.77)	0.55
3 rd	1 (100)	0	1	
Pre-ART provided (n=423)				
No	9 (90)	1 (10)	1	
Yes	375 (90.8)	38 (9.2)	0.91 (0.11,7.39)	0.93

In order to determine the independent risk factors for OIs, age, occupation, adherence to ART, period since ART initiation and WHO clinical stage at ART initiation were included in multivariate analysis as they all had a $p < 0.05$. Although gender had a p-value of 0.30 on univariate analysis, it was also included in the logistic model as it was one of the variables considered *a priori* to be associated with OI risk (50,51). Finally the independent risk factors for developing OIs were being jobless (Adjusted odds ratio [AOR] = 5.03, 95% CI= 2.13, 32.99), spending more than five years on ART (AOR= 4.34, 95% CI= 1.12-16.78) and starting ART at WHO clinical stage III (AOR= 4.88, 95% CI= 1.65-16.78). Development of OIs did not vary with gender and the age has no influence on OIs occurrence. (Table 6)

Table 6: Multivariate analysis for risk factors of OIs among patients on ART at Ruhengeri referral hospital

	Do not have OI		Have OI		COR (95%CI)	AOR (95%CI)	p-Value
	Frequency	%	Frequency	%			
Gender							
Female	249	91.9	22	8.1	1	1	0.06
Male	135	88.8	17	11.9	1.43 (0.73,2.78)	2.08 (0.96,4.53)	
Age (n=423)							
15-24 yrs	28	80	7	20	1	1	0.56 0.87 0.65 0.85
25-34 yrs	41	85.4	7	14.6	0.68 (0.22,2.16)	1.68 (0.30,9.55)	
35-44 yrs	128	93.4	9	6.6	0.28 (0.10,0.82)	1.17 (0.19,7.01)	
45-54yrs	131	91.6	12	8.4	0.37 (0.13,1.01)	1.50 (0.25,8.88)	
Over 55yrs	6	85.7	1	14.3	0.67 (0.07,6.47)	1.22 (0.16,9.01)	
Adherence to ART (n=422)							
<95%	34	79.1	9	20.1	1	1	0.09
>95%	349	92.1	30	7.9	0.32 (0.14,0.74)	0.42 (0.16,1.14)	
Occupation (n=423)							
Farmer	213	92.2	18	7.8	1	1	0.09 0.12 0.40 0.03
Jobless	14	70	6	30	5.07(1.73,14.79)	5.03(2.13,32.99)	
Paid employee	76	97.4	2	2.6	0.31 (0.07,1.37)	0.27 (0.06,1.25)	
Self employed	61	88.4	8	11.6	1.55 (0.64,3.74)	2.22 (0.86,6.04)	
Student	20	80	5	20	2.96 (0.99,8.81)	2.16 (0.36,12.94)	
ART period in years (n=423)							
< 5	100	97.1	3	2.9	1	1	0.03
> 5	284	88.7	36	11.3	4.2 (1.27,14.02)	4.34 (1.12,16.78)	
WHO clinical at ART initiation (n=423)							
1	164	96.8	6	3.5	1	1	0.05 0.004 0.16
2	118	90.1	13	9.9	3.01 (1.11,8.15)	2.94 (0.99,8.73)	
3	91	83.5	18	16.5	5.4 (2.07,14.1)	4.88 (1.65,14.40)	
4	11	84.6	2	15.4	5.0 (0.89,27.55)	4.23 (0.56,31.95)	

V. DISCUSSIONS OF THE RESULTS

This study assessed the prevalence of opportunistic infections among HIV positive patients on ART at Ruhengeri referral hospital. Our study population was aged between 15 and 83 years and the mean age was 43. Female subjects were in majority, most of the participants were married, with almost primary level of education and low economic status (subsistence farmers for the majority). These characteristics are comparable to other HIV positive patients found elsewhere in ART programmes in sub-Saharan Africa.(51)

The overall prevalence of OIs was 9.2%. This prevalence is very low compared to that of the countries in the region, namely 22.4% documented in Prevalence and Risk Factors for Opportunistic Infections in HIV Patients Receiving Antiretroviral Therapy in a Resource-Limited Setting in Nigeria, a descriptive and analytical cross-sectional study among adult HIV-infected patients receiving HAART(51). The study done on Magnitude of opportunistic infections and associated factors in HIV-infected adults on antiretroviral therapy in eastern Ethiopia found that about 48% of HIV/AIDS patients on ART had one or more OIs(52), this prevalence being much higher than that was found by our study. The prevalence found by this study is comparable to the one of USA and Canada which is 9% (53). The differences or similarities observed are mainly due to the health system structure of Rwanda where there is a decentralization of HIV services up to the health center level.

The commonest OIs have been tuberculosis accounting for (20%), oral candidiasis, pneumonia and STI accounting for 15.6% each. The most frequent OIs seen in our participants are similar to those documented in patients receiving ART in other settings like the one of Mitiku H, Weldegebreal F, Teklemariam Z. who worked on Magnitude of opportunistic infections and associated factors in HIV-infected adults on antiretroviral therapy in eastern Ethiopia(52), a study performed in Tertiary Care Hospital of China(28), and study by Delhi state AIDS control society done among HIV seropositive patients in Delhi region(54). They are mostly the same because the treatment is almost the same and the outcome has to be obviously the same.

A number of independent risk factors for the occurrence of OIs were identified in this study including being jobless, spending more than 5 years on ART, and starting ART at WHO clinical stage III. Being jobless as risk factor to developing OIs is found by this study and may be

justified by possible depression or lack of food causing under nutrition or stress of not having job. We would have been able to understand this more if we had data on nutritional status of patients and/or data on viral load. There is no other study that found jobless as a risk factor to developing OIs.

Spending more than five years on ART has been another risk factor to developing OIs found by this study. Findings from other studies show decline in risk of developing OIs as the time spent on ART increases. This was said in a study done in a Multicohort Analysis of HIV-infected Persons in the United States and Canada, 2000–2010 where the incidence rate of any first OI declined over the 3 calendar periods(53). The trend in OIs has not been shown in our studies due to the low frequency of OIs (39) over a period of 10 years.

Starting ART at Clinical stage III is another risk factor to develop OIs found in our study. This a finding common in such studies because other studies have found this as risk factor as well, such as in a study conducted in Ethiopia(28), and in Nigeria(37).

Poor adherence to ART has not been identified as risk factor to developing OIs in our study though it is mentioned in other studies(51). Our study couldn't detect the association because the majority of our sample population (89.8%) have and adherence above 95%.

Study limitations

The hospital where this study was conducted did not perform cultures for the diagnosis of OIs. Hence, the majority of the OIs were diagnosed clinically, which may have affected the diagnostic accuracy.

Due to the fact that data were collected from patients' clinical records kept by ARV service, it has been impossible to link patients' history with other files of internal medicine where patients are treated out of their ART appointments, which may have affected the prevalence accuracy.

We have not been able to measure all possible risk factors associated to the occurrence of OIs due to the following: not having records on CD4 progress from ART initiation because these data would help in assessing the efficacy of the treatment in increasing the level of CD4. Data on the weight of patients were not recorded regularly and systematically in their files. Due to this challenge we have not been able to measure the nutrition status of patients on ART or link the possibility of under-nutrition to the occurrence of OIs. Viral load was neither recorded in patients' file. This became a limit to the study because we have not been able to measure the association between the OIs occurrence and HIV virus amount.

VI. CONCLUSION AND RECOMMENDATIONS

The findings of this study show a prevalence of 9.2% meaning that Ruhengeri referral hospital still need to make effort in management of OIs.

From the findings of this study and the limitations, we recommend to:

- Create a link between the outpatients/ inpatients departments with the ARV service so that all records related to the health status of patients on ART are kept together.
- Request and record in the patients' files all results of required laboratory tests during follow up of patients as they come for their usual appointment.
- Record anthropometric measures as well, in patients' files every time when taken.
- Conduct a prospective cohort study in the same setting to better assess the risk factors for OIs.

References

1. WHO. HIV / AIDS: Confronting a Killer. World Heal Organ. 2003.
2. Tan IL, Smith BR, von Geldern G, Mateen FJ, McArthur JC. HIV-associated opportunistic infections of the CNS. *Lancet Neurol*. 2012
3. Masur H, Brooks JT, Benson CA, Holmes KK, Pau AK, Kaplan JE. Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents: Updated Guidelines From the Centers for Disease Control and Prevention, National Institutes of Health, and HIV Medicine Association of the Infectious Diseases Soc. *Clin Infect Dis*. 2014
4. Ioannidis J, Young T. HIV and AIDS HIV : prevention of opportunistic infections Search date December 2004 HIV and AIDS HIV : prevention of opportunistic infections. 2009
5. Donovan RM, Bush CE, Markowitz NP, Baxa DM, Saravolatz LD. Changes in virus load markers during AIDS-associated opportunistic diseases in human immunodeficiency virus-infected persons. *J Infect Dis*. 1996.
6. Quinn TC. HIV epidemiology and the effects of antiviral therapy on long-term consequences. *Aids*. 2008.
7. Domingues CSB, Waldman EA. Causes of death among people living with AIDS in the pre- And post-HAART eras in the City of São Paulo, Brazil. *PLoS One*. 2014
8. J.E. S, D.B. H, M.R. P, L.V. T. Causes of death among persons with aids in the era of highly active antiretroviral therapy: New York City. *Ann Intern Med*. 2006
9. Sidibe M. UNAIDS Data 2018. Program HIV/AIDS [Internet]. 2018
10. Profile D. District Profile.
11. 12 Th International Conference on Hiv Treatment , Pathogenesis , and Prevention Research (Interest) Meeting Report. 2018.
12. UNEP. The Emissions Gap Report 2014: A UNEP synthesis Report. Unep [Internet]. 2014;88. Available from: <http://www.unep.org/pdf/SEI.pdf>
13. Lawn SD, Butera ST. Contribution of Immune Activation to the Pathogenesis and Transmission of Human Immunodeficiency Virus Type 1 Infection. 2001.
14. Tsibris AMN, Hirsch MS. MINIREVIEW Antiretroviral Therapy in the Clinic □ . 2010
15. Therapy A, Huang L, Morris A, Justice AC, Pisani M, Crothers K. Critical Illness in HIV-Infected Patients in the Era of Combination Critical Illness in HIV-Infected Patients in the Era of Combination Antiretroviral Therapy. 2011;(May 2014).
16. Perbost I, Malafronte B, Pradier C, Santo LDI, Dunais B, Counillon E, et al. In the era of highly active antiretroviral therapy , why are HIV-infected patients still admitted to

- hospital for an inaugural opportunistic infection ? 2005.
17. Rubaihayo J, Tumwesigye NM, Konde-Lule J, Wamani H, Nakku-Joloba E, Makumbi F. Frequency and distribution patterns of opportunistic infections associated with HIV/AIDS in Uganda. *BMC Res Notes*. 2016.
 18. Moore RD. Natural History of Opportunistic Disease in an HIV-Infected Urban Clinical Cohort. *Ann Intern Med*. 2013.
 19. Weissberg D, Mubiru F, Kambugu A, Fehr J, Kiragga A, Von Braun A, et al. Ten years of antiretroviral therapy: Incidences, patterns and risk factors of opportunistic infections in an urban Ugandan cohort. *PLoS One*. 2018.
 20. Health P. School of Public Health Prevalence of HIV / AIDS related Opportunistic Infections among HIV Positive Patients in Rwanda. 2013.
 21. UNAIDS. Global Report 2013 - [un aids_global_report_2013_en.pdf](#) [Internet]. Un aids. 2013.
 22. International AIDS Society. Maximizing the benefits of antiretroviral therapy for key populations: A White Paper by the Key Affected Populations and Treatment as Prevention Working Groups of the International AIDS Society. 2014
 23. Schouten J, Wit FW, Stolte IG, Kootstra NA, Valk M Van Der, Geerlings SE. Cross-sectional Comparison of the Prevalence of Age-Associated Comorbidities and Their Risk Factors Between HIV-Infected and Uninfected Individuals : The AGE h IV Cohort Study. 2014.
 24. Aids G. GLOBAL AIDS UP. 2016;
 25. Sandhu A, Amanpreet &, Samra K. Opportunistic infections and disease implications in HIV/AIDS. *Int J Pharm Sci Invent ISSN* (Online [Internet]. 2013
 26. De Arruda Caceres N, Mazorra Coelho Vieira M, Fiorese Vieira I, Figueiredo Monteleone V, Moreira Neto LJ, Bonafe S. Opportunistic Infections in Aids Patients. *iMedPub Journals*. 2015
 27. Damtie D, Yismaw G, Woldeyohannes D, Anagaw B. Common opportunistic infections and their CD4 cell correlates among HIV-infected patients attending at antiretroviral therapy clinic. 2013
 28. Dabla V, Gupta AK, Singh I. Spectrum of opportunistic infections among HIV seropositive patients in Delhi region-a study by Delhi state AIDS control society. *J Med Disord* [Internet]. 2015
 29. Ministry of Health-Rwanda. National Guidelines for Prevention and Management of HIV and STIs. *Natl Guidel Prev Manag HIV STIs*. 2016;
 30. Günthard HF, Saag MS, Benson CA, Rio C, Eron JJ, Gallant JE, et al. HHS Public Access. 2016

31. WHO. Progress report: global health sector response to HIV 2000-2015. 2015;2000–15.
32. Rubaihayo J, Tumwesigye NM, Konde-Lule J. Trends in prevalence of selected opportunistic infections associated with HIV/AIDS in Uganda. *BMC Infect Dis* [Internet]. 2015
33. Urgessa F, Ararsa A, Ataro Z. AIDS & Clinical Research Prevalence and Associated Risk Factors of Opportunistic Infections among Anti-Retro Viral Treatment Na ï ve HIV / AIDS Infected Patients. 2018.
34. Gunda DW, Maganga SC, Nkandala I, Kilonzo SB, Mpondo BC, Shao ER, et al. Prevalence and Risk Factors of Active TB among Adult HIV Patients Receiving ART in Northwestern Tanzania : A Retrospective Cohort Study. 2018
35. Malwal FM, Muriuki G, Maru SS, Mwangangi EM. Prevalence of Opportunistic Infections in HIV- infected adult patients at Kenyatta National. 2016;5(3):163–8.
36. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV Recommendations from the Centers for Disease Control and Prevention
37. Bhuvana KB, Hema NG, Patil RT. Prevalence and risk factors for opportunistic infections in HIV patients who developed adverse drug reactions (ADRs) to antiretroviral therapy (ART) in a tertiary-care teaching hospital. *Natl J Physiol Pharm Pharmacol*. 2015.
38. Moges NA, Kassa GM. Prevalence of opportunistic infections and associated factors among HIV positive patients taking anti-retroviral therapy in DebreMarkos referral hospital, northwest Ethiopia. *J AIDS Clin Res*. 2014.
39. Gesesew H, Tsehaineh B, Massa D, Tesfay A, Kahsay H, Mwanri L. The role of social determinants on tuberculosis/HIV co-infection mortality in southwest Ethiopia: A retrospective cohort study. *BMC Res Notes*. 2016.
40. Carvour ML, Harms JP, Lynch CF, Mayer RR, Meier JL, Liu D, et al. Differential survival for men and women with HIV/AIDS-related neurologic diagnoses. *PLoS One*. 2015
41. Takarinda KC, Harries AD, Shiraishi RW, Mutasa-Apollo T, Abdul-Quader A, Mugurungi O. Gender-related differences in outcomes and attrition on antiretroviral treatment among an HIV-infected patient cohort in Zimbabwe: 2007-2010. *Int J Infect Dis*. 2015
42. Kim YJ, Woo JH, Kim MJ, Park DW, Song JY, Kim SW, et al. Opportunistic diseases among HIV-infected patients: A multicenter-nationwide Korean HIV/AIDS cohort study, 2006 to 2013. *Korean J Intern Med*. 2016
43. Emissions THE, Report GAP. The emissions gap report. 2014.
44. Manuscript A. NIH Public Access. 2015.

45. Diseases I. new england journal. 2015;
46. Galisteu KJ, Cardoso LV, Furini AA da C, Schiesari Junior A, Cesarino CB, Franco C, et al. Opportunistic infections among individuals with HIV-1/AIDS in the highly active antiretroviral therapy era at a Quaternary Level Care Teaching Hospital. *Rev Soc Bras Med Trop.* 2015
47. Rossouw T, Tucker JD, Van Zyl GU, Sikwesi K, Godfrey C. Barriers to HIV remission research in low- and middle-income countries. *J Int AIDS Soc* 2017
48. World T, Report H. *The World Health Report.* 2003
49. Coffin JM. *REDISCOVERING BIOLOGY HIV and AIDS.* Balt Johns Hopkins Univ Press. 1983;
50. Manuscript A, Factors TR. NIH Public Access. 2011
51. O Iroezindu M. Prevalence and Risk Factors for Opportunistic Infections in HIV Patients Receiving Antiretroviral Therapy in a Resource-Limited Setting in Nigeria. *J AIDS Clin Res [Internet].* 2013
52. Buchacz K, Lau B, Jing Y, Bosch R, Abraham AG, Gill MJ, et al. Incidence of AIDS-Defining Opportunistic Infections in a Multicohort Analysis of HIV-infected Persons in the United States and Canada , 2000 – 2010. 2016
53. Xiao J, Gao G, Li Y, Zhang W, Tian Y, Huang Y, et al. Spectrums of Opportunistic Infections and Malignancies in HIV-Infected Patients in Tertiary Care Hospital, China. Sued O, editor. *PLoS One.* 2013
54. Iroezindu MO, Ofondu EO, Hausler H, Wyk B Van. Prevalence and Risk Factors for Opportunistic Infections in HIV Patients AIDS & Clinical Prevalence and Risk Factors for Opportunistic Infections in HIV Patients Receiving Antiretroviral Therapy in a Resource-Limited Setting in Nigeria. 2013.